<!DOCTYPE html>

<!--[if lt IE 7]> <html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js lt-ie9 lt-ie8" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js lt-ie9" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en"> <!--<![endif]-->
<head><meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="IE=edge,chrome=1" http-equiv="X-UA-Compatible"/>
<meta content="width=device-width,initial-scale=1" name="viewport"/>
<link href="/xmlui/themes/Mirage2/images/favicon.ico" rel="shortcut icon"/>
<link href="/xmlui/themes/Mirage2/images/apple-touch-icon.png" rel="apple-touch-icon"/>
<meta content="DSpace 5.8" name="Generator"/>
<link href="https://fonts.googleapis.com/css?family=PT+Sans:400,700|Ubuntu:400,500,700italic|Droid+Sans:400,700" rel="stylesheet" type="text/css"/>
<link href="/xmlui/themes/Mirage2/styles/main.css" rel="stylesheet"/>
<link href="https://papyrus.bib.umontreal.ca:443/xmlui/description.xml" rel="search" title="DSpace" type="application/opensearchdescription+xml"/>
<script>
                //Clear default text of emty text areas on focus
                function tFocus(element)
                {
                if (element.value == ''){element.value='';}
                }
                //Clear default text of emty text areas on submit
                function tSubmit(form)
                {
                var defaultedElements = document.getElementsByTagName("textarea");
                for (var i=0; i != defaultedElements.length; i++){
                if (defaultedElements[i].value == ''){
                defaultedElements[i].value='';}}
                }
                //Disable pressing 'enter' key to submit a form (otherwise pressing 'enter' causes a submission to start over)
                function disableEnterKey(e)
                {
                var key;

                if(window.event)
                key = window.event.keyCode;     //Internet Explorer
                else
                key = e.which;     //Firefox and Netscape

                if(key == 13)  //if "Enter" pressed, then disable!
                return false;
                else
                return true;
                }
            </script><!--[if lt IE 9]>
                <script src="/xmlui/themes/Mirage2/vendor/html5shiv/dist/html5shiv.js"> </script>
                <script src="/xmlui/themes/Mirage2/vendor/respond/respond.min.js"> </script>
                <![endif]--><script src="/xmlui/themes/Mirage2/vendor/modernizr/modernizr.js"> </script><script src="https://www.bib.umontreal.ca/modele/urgence-udem/1.0.0/urgence-udem.js"></script>
<title>Modulating T Cell costimulation to prevent renal allograft rejection in nonhuman primates</title>
<meta content="Dr8axyf94eWBJ8HQjNW4eKxTumAAPsNbvRwpJYMbgGs" name="google-site-verification"/>
<link href="http://purl.org/dc/terms/" rel="schema.DCTERMS">
<link href="http://purl.org/dc/elements/1.1/" rel="schema.DC">
<meta content="Chen, Hui Fang" name="DC.contributor">
<meta content="Dumont, Louis" name="DC.contributor">
<meta content="Song, Lijun" name="DC.creator">
<meta content="2017-05-16T16:33:00Z" name="DCTERMS.dateAccepted" scheme="DCTERMS.W3CDTF">
<meta content="NO_RESTRICTION" name="DCTERMS.available" scheme="DCTERMS.W3CDTF" xml:lang="fr">
<meta content="2017-05-16T16:33:00Z" name="DCTERMS.available" scheme="DCTERMS.W3CDTF">
<meta content="2017-03-30" name="DCTERMS.issued" scheme="DCTERMS.W3CDTF"/>
<meta content="2016-08" name="DC.date" scheme="DCTERMS.W3CDTF"/>
<meta content="http://hdl.handle.net/1866/18560" name="DC.identifier" scheme="DCTERMS.URI"/>
<meta content="Blocage de la costimulation" name="DC.subject" xml:lang="fr"/>
<meta content="Transplantation rénale" name="DC.subject" xml:lang="fr"/>
<meta content="Primate non humain" name="DC.subject" xml:lang="fr"/>
<meta content="Rejet aigu" name="DC.subject" xml:lang="fr"/>
<meta content="Costimulation blockade" name="DC.subject" xml:lang="fr"/>
<meta content="Kidney transplantation" name="DC.subject" xml:lang="fr"/>
<meta content="Nonhuman primate" name="DC.subject" xml:lang="fr"/>
<meta content="Acute rejection" name="DC.subject" xml:lang="fr"/>
<meta content="Health Sciences - Medicine and Surgery / Sciences de la santé - Médecine et chirurgie (UMI : 0564)" name="DC.subject" xml:lang="fr"/>
<meta content="Modulating T Cell costimulation to prevent renal allograft rejection in nonhuman primates" name="DC.title" xml:lang="fr"/>
<meta content="Thèse ou mémoire / Thesis or Dissertation" name="DC.type"/>
<meta content="La transplantation d'organes est souvent la meilleure approche thérapeutique pour l'insuffisance organique au stade terminal. Le rejet de greffe est le principal obstacle pour une transplantation réussie, car cette dernière est le plus fréquemment réalisée entre individus génétiquement distincts. Les tissus ou organes transplantés sont généralement reconnus par le système immunitaire comme corps étrangers et sont rapidement détruits. Une série d'approches a été réalisée en clinique pour augmenter l'acceptation de la transplantation d’organes. Les immunosuppresseurs ont un rôle clé dans le combat contre le rejet de greffe. Actuellement, les résultats à court terme de la transplantation d'organes ont été considérablement améliorés avec l'émergence des inhibiteurs de la calcineurine (ICN), mais les résultats à long terme sont encore insatisfaisants. L'une des principales raisons est que les médicaments immunosuppresseurs actuels manquent de spécificité. Ces agents, en particulier ICN, sont considérés comme les facteurs de risque pour la perte tardive du greffon et les décès avec un greffon fonctionnel en raison de la toxicité des médicaments, de la sur-immunosuppression et d'autres effets secondaires. Ainsi, il y a un besoin urgent de rechercher de nouvelles thérapies idéales.

Les lymphocytes T jouent un rôle central dans l'initiation du rejet des allogreffes. La pleine activation des cellules T nécessite au moins deux signaux combinés, mais distincts. En plus du signal généré par l'interaction entre le récepteur des cellules T (TCR) et les complexes CMH-peptides, le second signal, appelé signal de costimulation qui est délivré par l'engagement du récepteur de costimulation avec son ligand, est essentiel. L'engagement du TCR en l'absence de signaux de costimulation peut donner lieu à l'anergie des cellules T, un état d'absence de réponse immunitaire. Les molécules costimulatrices acquièrent ainsi l'attention en tant que cibles thérapeutiques potentielles. Du fait que ces molécules soient largement limitées à des cellules T et/ou des cellules présentatrices d'antigène, cibler la voie de signalisation de costimulation offre la possibilité de moduler le système immunitaire d'une manière plus sélective par rapport à des agents immunosuppresseurs conventionnels. 

À ce jour, de nombreuses molécules costimulatrices ont été identifiées et certaines ont été testées en tant que cibles thérapeutiques dans des modèles de transplantation d'organes. Les axes CD28–CD80/86 et CD40–CD40L sont importants et les deux voies de signalisation de costimulation les mieux connues. Bélatacept est un variant de l'antigène 4 des lymphocytes T cytotoxiques-immunoglobuline G (CTLA4-Ig) qui bloque la voie de signalisation CD28–CD80/86. C'est le seul bloqueur de la costimulation à être approuvé pour utilisation clinique en transplantation d'organes. Par rapport à la thérapie basée sur les ICN pour les receveurs de transplantation rénale, les thérapies à base de bélatacept montrent un taux similaire de survie, une fonction supérieure du greffon et l'amélioration du profil de risque cardiovasculaire. Cependant, bélatacept est également associée à des taux plus élevés de rejet aigu et de syndrome lymphoprolifératif post-greffe (SLPG).

Dans notre étude, l'efficacité d'ASKP1240, un nouvel AcM anti-CD40 complètement humain qui bloque la voie de costimulation CD40–CD40L, a été évaluée sur la prévention du rejet d'allogreffe avec le modèle de transplantation rénale chez le singe cynomolgus. Quand ASKP1240 a été administré seul, il a réduit l'incidence du rejet aigu et a prolongé la survie de l'allogreffe rénale dépendamment de la dose administrée. L'acceptation de l'allogreffe rénale a été encore améliorée chez des singes qui ont reçus des traitements d'ASKP1240 combiné avec le tacrolimus (dose sub-thérapeutique) ou le mycophénolate mofétil (MMF). Le rejet aigu d'allogreffe a été totalement éliminé chez ces animaux et la médiane de survie du greffon rénal de ces groupes était significativement plus longue que ceux des groupes avec un traitement monothérapie. ASKP1240 a été bien toléré pour un traitement allant jusqu'à 180 jours. Il n'y avait pas d'effets secondaires évidents, y compris les complications thromboémboliques liées au médicament. L'administration d'ASKP1240 n'a pas induite de libération de cytokines.

Ensuite, nous avons étudié les effets d'ASP2409 sur le rejet de l'allogreffe rénale et la survie chez des singes cynomolgus. ASP2409 est une nouvelle CD86-sélective variante de CTLA4-Ig, qui possède une affinité de liaison au CD86 14 fois plus élevée que le bélatacept in vitro et une amélioration de la puissance immunosuppressive. Une haute dose d'ASP2409 en monothérapie a montré des résultats supérieurs dans la réduction de rejet aigu et la prolongation de la survie de l'allogreffe rénale en comparaison avec une faible dose d'ASP2409 en monothérapie. Une faible dose d'ASP2409 en combinaison avec tacrolimus (dose sub-thérapeutique) inhibe complètement le rejet aigu d'allogreffe et prolonge significativement la survie de l'allogreffe rénale par rapport à une monothérapie avec une faible dose d'ASP2409 ou une dose sub-thérapeutique de tacrolimus. La médiane de survie de l'allogreffe des animaux recevant un traitement à base d'une dose élevée d'ASP2409, bélatacept, ou une dose thérapeutique de tacrolimus étaient identiques (&gt; 91 jours). Les traitements à base d'une dose élevée d'ASP2409 présentaient de meilleurs résultats histopathologiques que le traitement à base de bélatacept. En outre, la fréquence des cellules FoxP3+ dans les allogreffes rénales a été observée plus haute dans les traitements à base d'ASP2409 et de bélatacept comparés aux traitements à base de tacrolimus. L'étude a également montré que ASP2409 est sans danger pour les animaux pour les doses qui ont été testées. Nous n'avons pas trouvé de graves effets secondaires liés à ASP2409 au cours des 91 jours d'étude. 

Collectivement, ces résultats suggèrent que la modulation sélective de la costimulation des cellules T avec des bloqueurs de la costimulation est une stratégie réalisable pour la prévention et le traitement du rejet d'allogreffe. ASKP1240 et ASP2409 sont tous deux des agents immunosuppresseurs prometteurs pour les régimes d'évitement ou de réduction des inhibiteurs de la calcineurine." name="DCTERMS.abstract" xml:lang="fr"/>
<meta content='Organ transplantation is often the best therapeutic approach for end-stage organ failure. Graft rejection is the major obstacle to successful transplantation because transplantation is most frequently carried out between genetically distinct individuals. Transplanted tissues or organs are usually recognized by the immune system as foreign and are rapidly destructed without immune interventions. A series of approaches have thus been applied in clinic to inhibit the allogenic immune responses and in turn increase organ transplant acceptance. Immunosuppressive drugs are the key players in the "war" against immune cell-mediated rejection of allogenic transplants. Currently, the use of calcineurin inhibitors (CNIs) has dramatically decreased the risk of acute transplant rejection and improved the short-term outcomes of organ transplantation, but the long-term outcomes are still unsatisfied. One of the main reasons causing unsatisfied long-term outcomes is that current immunosuppressive drugs do not specifically target immune cells that cause transplant rejection. These immunosuppressive agents, especially CNIs, are the risk factors for late graft loss and death with functioning graft (DWFG) due to drug toxicity, over-immunosuppression, and other side-effects. Thus there is an urgent need for seeking novel therapies that can selectively eliminate the alloreactive immune responses while preserving the integrity of the remainder of the host immune system.  

It has been known that T cells play a central role in initiating allograft rejection. Full activation of T cells requires at least two collaborative but distinct signals. The first signal is generated by the interaction between T cell receptor (TCR) and MHC-peptide complex. The second signal, termed costimulatory signal, is delivered through the engagement of costimulatory receptors by their ligands. Importantly, TCR engagement in the absence of costimulatory signals can result in T cell anergy, a state of T cell unresponsiveness. Costimulatory molecules thus gain attention as potential therapeutic targets. Because these molecules are primary expressed on T cells and/or antigen-presenting cells, targeting costimulatory signaling pathway offers the oppertumities to modulate immune system in a more selective way relative to conventional immunosuppressive agents. 

To date, numerous costimulatory molecules have been identified and some have been tested as therapeutic targets in organ transplant models. CD28–CD80/86 and CD40–CD40L axis are two important and the most well known costimulatory signaling pathways. Belatacept, a variant of cytotoxic T lymphocyte antigen 4-immunoglobulin G (CTLA4-Ig) that blocks CD28–CD80/86 signaling pathway, is the only costimulation blocker to be approved for clinical use in organ transplantation. Compared to CNI-based regimen for kidney transplant recipients, belatacept-based regimens show similar patient and graft survival rate, superior graft function, and improved cardiovascular risk profile. However, belatacept is also associated with higher rates of acute rejection and posttransplant lymphoproliferative disorder (PTLD). Disruption of CD40–CD40L interaction with anti-CD40L mAbs has also been demonstrated to be a reliable approach for preventing acute rejection and for prolonging allograft survival. Unfortunately, unexpected thromboembolic complications in preclinical studies and clinical trials discontinued the development of anti-CD40L mAbs. The main objective of this thesis is to identify the optimal T cell costimulation blockers that can show improved safety and non-inferior efficacy in promoting allograft acceptance relative to current costimulatory blocking agents.

Anti-CD40 mAbs are an alternative approach to block CD40–CD40L costimulatory pathway. CD40 is not involved in the stability of platelet thrombi and anti-CD40 mAbs are expected to not cause thromboembolic events. ASKP1240 is a novel fully human anti-CD40 mAb. In this study, the efficacy of ASKP1240 in the prevention of renal allograft rejection was evaluated in cynomolgus monkey kidney transplantation model. When ASKP1240 was administered alone, it dose-dependently reduced the incidence of acute rejection and prolonged renal allograft survival. Renal allograft acceptance was further improved in the monkey which received regiments using ASKP1240 combined with conventional immunosuppressive drugs tacrolimus (sub-therapeutic dose) or mycophenolate mofetil (MMF). Acute allograft rejection was totally eliminated in these animals and the kidney allograft median survival times (MST) of these groups were significantly longer than those of monotherapy groups. ASKP1240 administration did not induce cytokine release. This agent was well tolerated in monkey kidney transplant recipients during the 180-day treatment period. There were no obvious side effects including drug-related thromboembolic complications. 

Next, we tested the hypothesis that a CD86-selective variant of CTLA4-Ig might show non-inferior efficacy on the prevention of allograft rejection and prolongation of graft survival in comparison with belatacept. CD86 is the dominating ligand between the two natural ligands for CD28 in alloimmune response. Improvements in CD86 binding affinity of CTLA4-Igs confer increased immunosuppressive potency. A CD86-selective CTLA4-Ig variant may reach therapeutic levels of CD86 occupancy while occupies substantially less CD80 ligand than non-CD86-selective CTLA4-Igs. Preservation of CD80 signaling may be favoring to retain protective immunity and to improve safety of CTLA4-Ig therapy. This thesis investigated the effects of a novel CD86-selective CTLA4-Ig variant, ASP2409, on renal allograft rejection and survival in cynomolgus monkeys. ASP2409 possesses 14-fold higher in vitro CD86 binding affinity than belatacept and improved immunosuppressive potency. Compared to no-treatment control, low-dose (0.3 mg/kg) ASP2409 monotherapy significantly prolonged renal allograft survival (MST = 5 and 26 days, respectively) but did not decrease the incidence of acute rejection (8/8). The rate of acute renal allograft rejection was reduced in the group of high-dose ASP2409 monotherapy (2/7) and, correspondingly, a much longer MST (&gt;91 days) was shown in this group. Combination therapy of low-dose ASP2409 and tacrolimus (sub-therapeutic dose) completely eliminated acute allograft rejection and notably prolonged renal allograft survival (MST &gt;91 days). The MSTs of renal allografts in the animals receiving high-dose ASP2409-, belatacept-, and therapeutic dose tacrolimus-based immunosuppressive regimens were same (&gt;91 days). High-dose ASP2409-based regimens exhibited better histopathological results than belatacept-based regimen. Furthermore, higher frequencies of FoxP3+ Tregs in renal allografts were observed in ASP2409- and belatacept-based regimens compared to tacrolimus-based regimen. ASP2409 was also demonstrated to be safe for animals with the doses to be tested. There were no serious side effects related to ASP2409 to be found in term of 91-day study. 

This study demonstrates that ASKP1240 is as effective as anti-CD40L mAbs on inhibition of acute rejection and prolongation of renal allograft survival, and do not cause thromboembolic complications. Previous studies indicated that CNIs could diminish the effects of anti-CD40L mAbs. In our study, ASKP1240 in combination with tacrolimus or MMF shows improved efficiency. Furthermore, the effects of ASP2409 on promoting renal allograft acceptance are not inferior to belatacept. These results collectively suggest that ASKP1240 and ASP2409 both are the promising immunosuppressive agents for solid organ transplantation.' name="DCTERMS.abstract" xml:lang="fr"/>
<meta content="eng" name="DCTERMS.language" xml:lang="fr"/>
<meta content="Blocage de la costimulation; Transplantation rénale; Primate non humain; Rejet aigu; Costimulation blockade; Kidney transplantation; Nonhuman primate; Acute rejection; Health Sciences - Medicine and Surgery / Sciences de la santé - Médecine et chirurgie (UMI : 0564); Thèse ou mémoire / Thesis or Dissertation; Sciences biomédicales" name="citation_keywords"/>
<meta content="Modulating T Cell costimulation to prevent renal allograft rejection in nonhuman primates" name="citation_title"/>
<meta content="eng" name="citation_language"/>
<meta content="Song, Lijun" name="citation_author"/>
<meta content="https://papyrus.bib.umontreal.ca/xmlui/bitstream/1866/18560/4/Song_Lijun_2016_these.pdf" name="citation_pdf_url"/>
<meta content="2017-03-30" name="citation_date"/>
<meta content="https://papyrus.bib.umontreal.ca/xmlui/handle/1866/18560" name="citation_abstract_html_url"/>
<script type="text/x-mathjax-config">
                    MathJax.Hub.Config({
                      tex2jax: {
                        inlineMath: [['\\(','\\)']],
                        ignoreClass: "detail-field-data|detailtable|exception"
                      },
                      TeX: {
                        Macros: {
                          AA: '{\\mathring A}'
                        }
                      }
                    });
                </script><script src="//cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML" type="text/javascript"> </script>
</meta></meta></meta></meta></meta></meta></link></link></head><body>
<header>
<div class="navbar navbar-default navbar-static-top" role="navigation">
<div class="container">
<div class="hidden-xs hidden-sm hidden-md" id="um-bandeau" role="banner">
<nav class="um-nav um-nav-hidden" role="navigation">
<span class="hidden">Liens externes</span>
<ul>
<li>
<a href="https://www.umontreal.ca/#udemwww-search-personne">Directories</a>
</li>
<li>
<a href="http://www.umontreal.ca/repertoires/facultes.html">Faculties</a>
</li>
<li>
<a href="http://www.bib.umontreal.ca/">Libraries</a>
</li>
<li>
<a href="http://plancampus.umontreal.ca/">Campus maps</a>
</li>
<li>
<a href="http://www.umontreal.ca/index/az.html">Sites A to Z</a>
</li>
<li>
<a>My UdeM</a>
<ul>
<li>
<a href="https://monudem.umontreal.ca/">My UdeM Portal</a>
</li>
<li>
<a href="https://outlook.umontreal.ca">My email</a>
</li>
<li>
<a href="https://studium.umontreal.ca/">StudiUM</a>
</li>
</ul>
</li>
</ul>
</nav>
<form action="https://google.com/cse" class="um-recherche" id="um-recherche" role="search">
<input name="cx" type="hidden" value="011926736769028447783:qlpu3so2kqq"/><input name="ie" type="hidden" value="ISO-8859-1"/><label class="hidden" for="um-boite-recherche">Search in : </label><span class="um-boite-bouton"><input class="um-boite" id="um-boite-recherche" maxlength="255" name="q" placeholder="UdeM" title="Type your search text" type="text" value=""/><input alt="Search in : " class="um-bouton" src="/xmlui/themes/Mirage2/images/bib-umontreal/loupe.gif" type="image"/></span>
</form>
</div>
<div class="hidden-xs hidden-sm visible-md visible-lg" id="papyrus-deco">
<img alt="Dessin du pavillon Roger Gaudry/Sketch of Roger Gaudry Building" border="0" height="89px" src="/xmlui/themes/Mirage2/images/UdeM.gif" title="Dessin du pavillon Roger Gaudry/Sketch of Roger Gaudry Building" width="193px"/></div>
<div class="navbar-header">
<button class="navbar-toggle" data-toggle="offcanvas" type="button"><span class="sr-only">Toggle navigation</span><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button><a class="navbar-brand hidden-xs hidden-sm visible-md visible-lg um-logo-md-lg" href="http://www.umontreal.ca/english/index.html"><img alt="University Home page" src="/xmlui/themes/Mirage2/images/logo-UdeM.svg" title="Back to University Home page"/></a><a class="navbar-brand hidden-xs visible-sm hidden-md hidden-lg um-logo-sm" href="http://www.umontreal.ca/english/index.html"><img alt="University Home page" src="/xmlui/themes/Mirage2/images/logo-UdeM.svg" title="Back to University Home page"/></a><a class="navbar-brand visible-xs hidden-sm hidden-md hidden-lg um-logo-xs" href="http://www.umontreal.ca/english/index.html"><img alt="University Home page" src="/xmlui/themes/Mirage2/images/logo-UdeM.svg" title="Back to University Home page"/></a>
<div class="navbar-brand separateur visible-xs hidden-sm hidden-md hidden-lg um-sep-site-xs"></div>
<div class="navbar-brand separateur hidden-xs visible-sm hidden-md hidden-lg um-sep-site-sm"></div>
<div class="navbar-brand separateur visible-md visible-lg hidden-xs hidden-sm um-sep-site-md-lg"></div>
<div class="navbar-brand visible-md visible-lg hidden-xs hidden-sm um-titre-site-md-lg">
<span class="papyrus-signature">Papyrus</span> :
                                Institutional Repository</div>
<div class="navbar-brand hidden-xs visible-sm hidden-md hidden-lg um-titre-site-sm">
<span class="papyrus-signature">Papyrus</span>
<br/>Institutional Repository</div>
<div class="navbar-brand visible-xs hidden-sm hidden-md hidden-lg um-titre-site-xs">
<span class="papyrus-signature">Papyrus</span>
</div>
<div class="navbar-header pull-right visible-xs hidden-sm hidden-md hidden-lg">
<ul class="nav nav-pills pull-left">
<li class="dropdown" id="ds-language-selection-xs">
<button class="dropdown-toggle navbar-toggle navbar-link" data-toggle="dropdown" href="#" id="language-dropdown-toggle-xs" role="button"><b aria-hidden="true" class="visible-xs glyphicon glyphicon-globe"></b></button>
<ul aria-labelledby="language-dropdown-toggle-xs" class="dropdown-menu pull-right" data-no-collapse="true" role="menu">
<li role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/18560?locale-attribute=fr&amp;show=full">français</a>
</li>
<li class="disabled" role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/18560?locale-attribute=en&amp;show=full">English</a>
</li>
</ul>
</li>
<li>
<form action="/xmlui/login" method="get" style="display: inline">
<button class="navbar-toggle navbar-link"><b aria-hidden="true" class="visible-xs glyphicon glyphicon-user"></b></button>
</form>
</li>
</ul>
</div>
</div>
<div class="navbar-header pull-right hidden-xs">
<div class="nav-language-and-login-lg hidden-xs hidden-sm hidden-md">
<ul class="nav navbar-nav pull-right">
<li class="dropdown" id="ds-language-selection">
<a class="dropdown-toggle" data-toggle="dropdown" href="#" id="language-dropdown-toggle" role="button"><span class="hidden-xs">English <b class="caret"></b></span></a>
<ul aria-labelledby="language-dropdown-toggle" class="dropdown-menu pull-right" data-no-collapse="true" role="menu">
<li role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/18560?locale-attribute=fr&amp;show=full">français</a>
</li>
<li class="disabled" role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/18560?locale-attribute=en&amp;show=full">English</a>
</li>
</ul>
</li>
</ul>
<ul class="nav navbar-nav pull-right">
<li>
<a href="/xmlui/login"><span class="hidden-xs">Login</span></a>
</li>
</ul>
</div>
<div class="hidden-lg">
<ul class="nav navbar-nav pull-right">
<li class="dropdown" id="ds-language-selection">
<a class="dropdown-toggle" data-toggle="dropdown" href="#" id="language-dropdown-toggle" role="button"><span class="hidden-xs">English <b class="caret"></b></span></a>
<ul aria-labelledby="language-dropdown-toggle" class="dropdown-menu pull-right" data-no-collapse="true" role="menu">
<li role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/18560?locale-attribute=fr&amp;show=full">français</a>
</li>
<li class="disabled" role="presentation">
<a href="https://papyrus.bib.umontreal.ca:443/xmlui/handle/1866/18560?locale-attribute=en&amp;show=full">English</a>
</li>
</ul>
</li>
</ul>
<ul class="nav navbar-nav pull-right">
<li>
<a href="/xmlui/login"><span class="hidden-xs">Login</span></a>
</li>
</ul>
</div>
<button class="navbar-toggle visible-sm" data-toggle="offcanvas" type="button"><span class="sr-only">Toggle navigation</span><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button>
</div>
</div>
</div>
</header>
<div class="trail-wrapper hidden-print">
<div class="container">
<div class="row">
<div class="col-xs-12">
<div class="breadcrumb dropdown visible-xs">
<a class="dropdown-toggle" data-toggle="dropdown" href="#" id="trail-dropdown-toggle" role="button">View Item <b class="caret"></b></a>
<ul aria-labelledby="trail-dropdown-toggle" class="dropdown-menu" role="menu">
<li role="presentation">
<a href="/xmlui/" role="menuitem"><i aria-hidden="true" class="glyphicon glyphicon-home"></i>  Home</a>
</li>
<li role="presentation">
<a href="/xmlui/handle/1866/1349" role="menuitem">Faculté de médecine</a>
</li>
<li role="presentation">
<a href="/xmlui/handle/1866/2591" role="menuitem">Faculté de médecine – Thèses et mémoires</a>
</li>
<li class="disabled" role="presentation">
<a href="#" role="menuitem">View Item</a>
</li>
</ul>
</div>
<ul class="breadcrumb hidden-xs">
<li>
<i aria-hidden="true" class="glyphicon glyphicon-home"></i>  <a href="/xmlui/">Home</a>
</li>
<li>
<a href="/xmlui/handle/1866/1349">Faculté de médecine</a>
</li>
<li>
<a href="/xmlui/handle/1866/2591">Faculté de médecine – Thèses et mémoires</a>
</li>
<li class="active">View Item</li>
</ul>
</div>
</div>
</div>
</div>
<div class="hidden" id="no-js-warning-wrapper">
<div id="no-js-warning">
<div class="notice failure">JavaScript is disabled for your browser. Some features of this site may not work without it.</div>
</div>
</div>
<div class="container" id="main-container">
<div class="row row-offcanvas row-offcanvas-left">
<div class="horizontal-slider clearfix">
<div class="col-xs-6 col-sm-3 sidebar-offcanvas" id="sidebar" role="navigation">
<div class="word-break hidden-print" id="ds-options">
<div class="ds-option-set" id="ds-search-option">
<form action="/xmlui/discover" class="" id="ds-search-form" method="post">
<fieldset>
<div class="input-group">
<input class="ds-text-field form-control" name="query" placeholder="Search" type="text"/><span class="input-group-btn"><button class="ds-button-field btn" title="Go"><span aria-hidden="true" class="glyphicon glyphicon-search"></span></button></span>
</div>
<div class="radio">
<label><input checked="" id="ds-search-form-scope-all" name="scope" type="radio" value=""/>Search Papyrus</label>
</div>
<div class="radio">
<label><input id="ds-search-form-scope-container" name="scope" type="radio" value="1866/2591"/>Search this Collection</label>
</div>
</fieldset>
</form>
</div>
<h2 class="ds-option-set-head h6">My Account</h2>
<div class="list-group" id="aspect_viewArtifacts_Navigation_list_account">
<div class="list-group-item ds-option details_Papyrus" id="aspect_eperson_Navigation_item_details_Papyrus">To submit an item or subscribe to email alerts.</div>
<div class="list-group-item ds-option">
<span class="bold"><a href="/xmlui/login">Login</a></span>
</div>
<a class="list-group-item ds-option" href="/xmlui/register">New user?</a>
</div>
<h2 class="ds-option-set-head h6">Browse</h2>
<div class="list-group" id="aspect_viewArtifacts_Navigation_list_browse">
<a class="list-group-item active"><span class="h5 list-group-item-heading h5">All of Papyrus</span></a><a class="list-group-item ds-option" href="/xmlui/community-list">Communities and Collections</a><a class="list-group-item ds-option" href="/xmlui/browse?type=title">Titles</a><a class="list-group-item ds-option" href="/xmlui/browse?type=dateissued">Issue Dates</a><a class="list-group-item ds-option" href="/xmlui/browse?type=author">Authors</a><a class="list-group-item ds-option" href="/xmlui/browse?type=advisor">Advisors</a><a class="list-group-item ds-option" href="/xmlui/browse?type=subject">Subjects</a><a class="list-group-item ds-option" href="/xmlui/browse?type=discipline">Disciplines</a><a class="list-group-item ds-option" href="/xmlui/browse?type=affiliation">Affiliation</a><a class="list-group-item ds-option" href="/xmlui/browse?type=titleindex">Titles index</a><a class="list-group-item active"><span class="h5 list-group-item-heading h5">This Collection</span></a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2591/browse?type=title">Titles</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2591/browse?type=dateissued">Issue Dates</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2591/browse?type=author">Authors</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2591/browse?type=advisor">Advisors</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2591/browse?type=subject">Subjects</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2591/browse?type=discipline">Disciplines</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2591/browse?type=affiliation">Affiliation</a><a class="list-group-item ds-option" href="/xmlui/handle/1866/2591/browse?type=titleindex">Titles index</a>
</div>
<div class="list-group" id="aspect_viewArtifacts_Navigation_list_context"></div>
<div class="list-group" id="aspect_viewArtifacts_Navigation_list_administrative"></div>
<div class="list-group" id="aspect_discovery_Navigation_list_discovery"></div>
<h2 class="ds-option-set-head h6">Statistics</h2>
<div class="list-group" id="aspect_statistics_Navigation_list_statistics">
<a class="list-group-item ds-option" href="/xmlui/handle/1866/18560/statistics">View Usage Statistics</a>
</div>
</div>
</div>
<div class="col-xs-12 col-sm-12 col-md-9 main-content">
<div>
<div class="ds-static-div primary" id="aspect_artifactbrowser_ItemViewer_div_item-view">
<p class="ds-paragraph item-view-toggle item-view-toggle-top">
<span class="item-view-toggle"><a href="/xmlui/handle/1866/18560">Show item record</a></span>
</p>
<!-- External Metadata URL: cocoon://metadata/handle/1866/18560/mets.xml-->
<h2 class="page-header first-page-header">Modulating T Cell costimulation to prevent renal allograft rejection in nonhuman primates</h2>
<div class="ds-table-responsive">
<table class="ds-includeSet-table detailtable table table-striped table-hover">
<tr class="ds-table-row odd">
<td class="label-cell">dc.contributor.advisor</td><td class="word-break">Chen, Hui Fang</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.contributor.advisor</td><td class="word-break">Dumont, Louis</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.contributor.author</td><td class="word-break">Song, Lijun</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.date.accessioned</td><td class="word-break">2017-05-16T16:33:00Z</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.date.available</td><td class="word-break">NO_RESTRICTION</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.date.available</td><td class="word-break">2017-05-16T16:33:00Z</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.date.issued</td><td class="word-break">2017-03-30</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.date.submitted</td><td class="word-break">2016-08</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.identifier.uri</td><td class="word-break">http://hdl.handle.net/1866/18560</td><td></td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Blocage de la costimulation</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">Transplantation rénale</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Primate non humain</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">Rejet aigu</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Costimulation blockade</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">Kidney transplantation</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject</td><td class="word-break">Nonhuman primate</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.subject</td><td class="word-break">Acute rejection</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.subject.other</td><td class="word-break">Health Sciences - Medicine and Surgery / Sciences de la santé - Médecine et chirurgie (UMI : 0564)</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dc.title</td><td class="word-break">Modulating T Cell costimulation to prevent renal allograft rejection in nonhuman primates</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dc.type</td><td class="word-break">Thèse ou mémoire / Thesis or Dissertation</td><td></td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">etd.degree.discipline</td><td class="word-break">Sciences biomédicales</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">etd.degree.grantor</td><td class="word-break">Université de Montréal</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">etd.degree.level</td><td class="word-break">Doctorat / Doctoral</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">etd.degree.name</td><td class="word-break">Ph. D.</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dcterms.abstract</td><td class="word-break">La transplantation d'organes est souvent la meilleure approche thérapeutique pour l'insuffisance organique au stade terminal. Le rejet de greffe est le principal obstacle pour une transplantation réussie, car cette dernière est le plus fréquemment réalisée entre individus génétiquement distincts. Les tissus ou organes transplantés sont généralement reconnus par le système immunitaire comme corps étrangers et sont rapidement détruits. Une série d'approches a été réalisée en clinique pour augmenter l'acceptation de la transplantation d’organes. Les immunosuppresseurs ont un rôle clé dans le combat contre le rejet de greffe. Actuellement, les résultats à court terme de la transplantation d'organes ont été considérablement améliorés avec l'émergence des inhibiteurs de la calcineurine (ICN), mais les résultats à long terme sont encore insatisfaisants. L'une des principales raisons est que les médicaments immunosuppresseurs actuels manquent de spécificité. Ces agents, en particulier ICN, sont considérés comme les facteurs de risque pour la perte tardive du greffon et les décès avec un greffon fonctionnel en raison de la toxicité des médicaments, de la sur-immunosuppression et d'autres effets secondaires. Ainsi, il y a un besoin urgent de rechercher de nouvelles thérapies idéales.

Les lymphocytes T jouent un rôle central dans l'initiation du rejet des allogreffes. La pleine activation des cellules T nécessite au moins deux signaux combinés, mais distincts. En plus du signal généré par l'interaction entre le récepteur des cellules T (TCR) et les complexes CMH-peptides, le second signal, appelé signal de costimulation qui est délivré par l'engagement du récepteur de costimulation avec son ligand, est essentiel. L'engagement du TCR en l'absence de signaux de costimulation peut donner lieu à l'anergie des cellules T, un état d'absence de réponse immunitaire. Les molécules costimulatrices acquièrent ainsi l'attention en tant que cibles thérapeutiques potentielles. Du fait que ces molécules soient largement limitées à des cellules T et/ou des cellules présentatrices d'antigène, cibler la voie de signalisation de costimulation offre la possibilité de moduler le système immunitaire d'une manière plus sélective par rapport à des agents immunosuppresseurs conventionnels. 

À ce jour, de nombreuses molécules costimulatrices ont été identifiées et certaines ont été testées en tant que cibles thérapeutiques dans des modèles de transplantation d'organes. Les axes CD28–CD80/86 et CD40–CD40L sont importants et les deux voies de signalisation de costimulation les mieux connues. Bélatacept est un variant de l'antigène 4 des lymphocytes T cytotoxiques-immunoglobuline G (CTLA4-Ig) qui bloque la voie de signalisation CD28–CD80/86. C'est le seul bloqueur de la costimulation à être approuvé pour utilisation clinique en transplantation d'organes. Par rapport à la thérapie basée sur les ICN pour les receveurs de transplantation rénale, les thérapies à base de bélatacept montrent un taux similaire de survie, une fonction supérieure du greffon et l'amélioration du profil de risque cardiovasculaire. Cependant, bélatacept est également associée à des taux plus élevés de rejet aigu et de syndrome lymphoprolifératif post-greffe (SLPG).

Dans notre étude, l'efficacité d'ASKP1240, un nouvel AcM anti-CD40 complètement humain qui bloque la voie de costimulation CD40–CD40L, a été évaluée sur la prévention du rejet d'allogreffe avec le modèle de transplantation rénale chez le singe cynomolgus. Quand ASKP1240 a été administré seul, il a réduit l'incidence du rejet aigu et a prolongé la survie de l'allogreffe rénale dépendamment de la dose administrée. L'acceptation de l'allogreffe rénale a été encore améliorée chez des singes qui ont reçus des traitements d'ASKP1240 combiné avec le tacrolimus (dose sub-thérapeutique) ou le mycophénolate mofétil (MMF). Le rejet aigu d'allogreffe a été totalement éliminé chez ces animaux et la médiane de survie du greffon rénal de ces groupes était significativement plus longue que ceux des groupes avec un traitement monothérapie. ASKP1240 a été bien toléré pour un traitement allant jusqu'à 180 jours. Il n'y avait pas d'effets secondaires évidents, y compris les complications thromboémboliques liées au médicament. L'administration d'ASKP1240 n'a pas induite de libération de cytokines.

Ensuite, nous avons étudié les effets d'ASP2409 sur le rejet de l'allogreffe rénale et la survie chez des singes cynomolgus. ASP2409 est une nouvelle CD86-sélective variante de CTLA4-Ig, qui possède une affinité de liaison au CD86 14 fois plus élevée que le bélatacept in vitro et une amélioration de la puissance immunosuppressive. Une haute dose d'ASP2409 en monothérapie a montré des résultats supérieurs dans la réduction de rejet aigu et la prolongation de la survie de l'allogreffe rénale en comparaison avec une faible dose d'ASP2409 en monothérapie. Une faible dose d'ASP2409 en combinaison avec tacrolimus (dose sub-thérapeutique) inhibe complètement le rejet aigu d'allogreffe et prolonge significativement la survie de l'allogreffe rénale par rapport à une monothérapie avec une faible dose d'ASP2409 ou une dose sub-thérapeutique de tacrolimus. La médiane de survie de l'allogreffe des animaux recevant un traitement à base d'une dose élevée d'ASP2409, bélatacept, ou une dose thérapeutique de tacrolimus étaient identiques (&gt; 91 jours). Les traitements à base d'une dose élevée d'ASP2409 présentaient de meilleurs résultats histopathologiques que le traitement à base de bélatacept. En outre, la fréquence des cellules FoxP3+ dans les allogreffes rénales a été observée plus haute dans les traitements à base d'ASP2409 et de bélatacept comparés aux traitements à base de tacrolimus. L'étude a également montré que ASP2409 est sans danger pour les animaux pour les doses qui ont été testées. Nous n'avons pas trouvé de graves effets secondaires liés à ASP2409 au cours des 91 jours d'étude. 

Collectivement, ces résultats suggèrent que la modulation sélective de la costimulation des cellules T avec des bloqueurs de la costimulation est une stratégie réalisable pour la prévention et le traitement du rejet d'allogreffe. ASKP1240 et ASP2409 sont tous deux des agents immunosuppresseurs prometteurs pour les régimes d'évitement ou de réduction des inhibiteurs de la calcineurine.</td><td>fr</td>
</tr>
<tr class="ds-table-row even">
<td class="label-cell">dcterms.abstract</td><td class="word-break">Organ transplantation is often the best therapeutic approach for end-stage organ failure. Graft rejection is the major obstacle to successful transplantation because transplantation is most frequently carried out between genetically distinct individuals. Transplanted tissues or organs are usually recognized by the immune system as foreign and are rapidly destructed without immune interventions. A series of approaches have thus been applied in clinic to inhibit the allogenic immune responses and in turn increase organ transplant acceptance. Immunosuppressive drugs are the key players in the "war" against immune cell-mediated rejection of allogenic transplants. Currently, the use of calcineurin inhibitors (CNIs) has dramatically decreased the risk of acute transplant rejection and improved the short-term outcomes of organ transplantation, but the long-term outcomes are still unsatisfied. One of the main reasons causing unsatisfied long-term outcomes is that current immunosuppressive drugs do not specifically target immune cells that cause transplant rejection. These immunosuppressive agents, especially CNIs, are the risk factors for late graft loss and death with functioning graft (DWFG) due to drug toxicity, over-immunosuppression, and other side-effects. Thus there is an urgent need for seeking novel therapies that can selectively eliminate the alloreactive immune responses while preserving the integrity of the remainder of the host immune system.  

It has been known that T cells play a central role in initiating allograft rejection. Full activation of T cells requires at least two collaborative but distinct signals. The first signal is generated by the interaction between T cell receptor (TCR) and MHC-peptide complex. The second signal, termed costimulatory signal, is delivered through the engagement of costimulatory receptors by their ligands. Importantly, TCR engagement in the absence of costimulatory signals can result in T cell anergy, a state of T cell unresponsiveness. Costimulatory molecules thus gain attention as potential therapeutic targets. Because these molecules are primary expressed on T cells and/or antigen-presenting cells, targeting costimulatory signaling pathway offers the oppertumities to modulate immune system in a more selective way relative to conventional immunosuppressive agents. 

To date, numerous costimulatory molecules have been identified and some have been tested as therapeutic targets in organ transplant models. CD28–CD80/86 and CD40–CD40L axis are two important and the most well known costimulatory signaling pathways. Belatacept, a variant of cytotoxic T lymphocyte antigen 4-immunoglobulin G (CTLA4-Ig) that blocks CD28–CD80/86 signaling pathway, is the only costimulation blocker to be approved for clinical use in organ transplantation. Compared to CNI-based regimen for kidney transplant recipients, belatacept-based regimens show similar patient and graft survival rate, superior graft function, and improved cardiovascular risk profile. However, belatacept is also associated with higher rates of acute rejection and posttransplant lymphoproliferative disorder (PTLD). Disruption of CD40–CD40L interaction with anti-CD40L mAbs has also been demonstrated to be a reliable approach for preventing acute rejection and for prolonging allograft survival. Unfortunately, unexpected thromboembolic complications in preclinical studies and clinical trials discontinued the development of anti-CD40L mAbs. The main objective of this thesis is to identify the optimal T cell costimulation blockers that can show improved safety and non-inferior efficacy in promoting allograft acceptance relative to current costimulatory blocking agents.

Anti-CD40 mAbs are an alternative approach to block CD40–CD40L costimulatory pathway. CD40 is not involved in the stability of platelet thrombi and anti-CD40 mAbs are expected to not cause thromboembolic events. ASKP1240 is a novel fully human anti-CD40 mAb. In this study, the efficacy of ASKP1240 in the prevention of renal allograft rejection was evaluated in cynomolgus monkey kidney transplantation model. When ASKP1240 was administered alone, it dose-dependently reduced the incidence of acute rejection and prolonged renal allograft survival. Renal allograft acceptance was further improved in the monkey which received regiments using ASKP1240 combined with conventional immunosuppressive drugs tacrolimus (sub-therapeutic dose) or mycophenolate mofetil (MMF). Acute allograft rejection was totally eliminated in these animals and the kidney allograft median survival times (MST) of these groups were significantly longer than those of monotherapy groups. ASKP1240 administration did not induce cytokine release. This agent was well tolerated in monkey kidney transplant recipients during the 180-day treatment period. There were no obvious side effects including drug-related thromboembolic complications. 

Next, we tested the hypothesis that a CD86-selective variant of CTLA4-Ig might show non-inferior efficacy on the prevention of allograft rejection and prolongation of graft survival in comparison with belatacept. CD86 is the dominating ligand between the two natural ligands for CD28 in alloimmune response. Improvements in CD86 binding affinity of CTLA4-Igs confer increased immunosuppressive potency. A CD86-selective CTLA4-Ig variant may reach therapeutic levels of CD86 occupancy while occupies substantially less CD80 ligand than non-CD86-selective CTLA4-Igs. Preservation of CD80 signaling may be favoring to retain protective immunity and to improve safety of CTLA4-Ig therapy. This thesis investigated the effects of a novel CD86-selective CTLA4-Ig variant, ASP2409, on renal allograft rejection and survival in cynomolgus monkeys. ASP2409 possesses 14-fold higher in vitro CD86 binding affinity than belatacept and improved immunosuppressive potency. Compared to no-treatment control, low-dose (0.3 mg/kg) ASP2409 monotherapy significantly prolonged renal allograft survival (MST = 5 and 26 days, respectively) but did not decrease the incidence of acute rejection (8/8). The rate of acute renal allograft rejection was reduced in the group of high-dose ASP2409 monotherapy (2/7) and, correspondingly, a much longer MST (&gt;91 days) was shown in this group. Combination therapy of low-dose ASP2409 and tacrolimus (sub-therapeutic dose) completely eliminated acute allograft rejection and notably prolonged renal allograft survival (MST &gt;91 days). The MSTs of renal allografts in the animals receiving high-dose ASP2409-, belatacept-, and therapeutic dose tacrolimus-based immunosuppressive regimens were same (&gt;91 days). High-dose ASP2409-based regimens exhibited better histopathological results than belatacept-based regimen. Furthermore, higher frequencies of FoxP3+ Tregs in renal allografts were observed in ASP2409- and belatacept-based regimens compared to tacrolimus-based regimen. ASP2409 was also demonstrated to be safe for animals with the doses to be tested. There were no serious side effects related to ASP2409 to be found in term of 91-day study. 

This study demonstrates that ASKP1240 is as effective as anti-CD40L mAbs on inhibition of acute rejection and prolongation of renal allograft survival, and do not cause thromboembolic complications. Previous studies indicated that CNIs could diminish the effects of anti-CD40L mAbs. In our study, ASKP1240 in combination with tacrolimus or MMF shows improved efficiency. Furthermore, the effects of ASP2409 on promoting renal allograft acceptance are not inferior to belatacept. These results collectively suggest that ASKP1240 and ASP2409 both are the promising immunosuppressive agents for solid organ transplantation.</td><td>fr</td>
</tr>
<tr class="ds-table-row odd">
<td class="label-cell">dcterms.language</td><td class="word-break">eng</td><td>fr</td>
</tr>
</table>
</div>
<span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&amp;rft_id=http%3A%2F%2Fhdl.handle.net%2F1866%2F18560&amp;rfr_id=info%3Asid%2Fdspace.org%3Arepository&amp;rft.degree=Sciences+biom%C3%A9dicales&amp;rft.degree=Universit%C3%A9+de+Montr%C3%A9al&amp;rft.degree=Doctorat+%2F+Doctoral&amp;rft.degree=Ph.+D."> ﻿ 
        </span>
<h3>Files in this item</h3>
<div class="file-list">
<div class="file-wrapper row">
<div class="col-xs-6 col-sm-3">
<div class="thumbnail-wrapper">
<a class="image-link" href="/xmlui/bitstream/handle/1866/18560/Song_Lijun_2016_these.pdf?sequence=4&amp;isAllowed=y"><img alt="Thumbnail" class="thumbnail-papyrus" src="/xmlui/bitstream/handle/1866/18560/Song_Lijun_2016_these.pdf.jpg?sequence=6&amp;isAllowed=y"/></a>
<div class="imageoverlay">
<img height="49" src="/xmlui/themes/Mirage2/images/mimes/mime_icone_pdf.png" style="height: 49px;" width="44"/></div>
</div>
</div>
<div class="col-xs-6 col-sm-7">
<dl class="file-metadata dl-horizontal">
<dt>Name:</dt>
<dd class="word-break" title="Song_Lijun_2016_these.pdf">
<a href="/xmlui/bitstream/handle/1866/18560/Song_Lijun_2016_these.pdf?sequence=4&amp;isAllowed=y">Song_Lijun_2016_these.pdf</a>
</dd>
<dt>Size:</dt>
<dd class="word-break">4.048Mb</dd>
<dt>Format:</dt>
<dd class="word-break">PDF</dd>
<dt>Description:</dt>
<dd class="word-break" title="thèse">thèse</dd>
</dl>
</div>
</div>
</div>
<h3 class="ds-list-head">This item appears in the following Collection(s)</h3>
<ul class="ds-referenceSet-list">
<!-- External Metadata URL: cocoon://metadata/handle/1866/2621/mets.xml-->
<li>
<a href="/xmlui/handle/1866/2621">Thèses et mémoires électroniques de l’Université de Montréal</a> [18270]<br/>
</li>
<!-- External Metadata URL: cocoon://metadata/handle/1866/2591/mets.xml-->
<li>
<a href="/xmlui/handle/1866/2591">Faculté de médecine – Thèses et mémoires</a> [4267]<br/>
</li>
</ul>
<p class="ds-paragraph item-view-toggle item-view-toggle-bottom">
<span class="item-view-toggle"><a href="/xmlui/handle/1866/18560">Show item record</a></span>
</p>
</div>
</div>
<div class="visible-xs visible-sm">
<footer>
<div class="row">
<hr/>
<div class="col-xs-7 col-sm-8">
<div>
<a href="http://www.dspace.org/" target="_blank">DSpace software</a>
                        [version 5.8 XMLUI],
                        copyright © 2002-2015  <a href="http://www.duraspace.org/" target="_blank">DuraSpace</a>
</div>
<div class="hidden-print">
<a href="/xmlui/contact">Contact Us</a> | <a href="/xmlui/feedback">Send Feedback</a>
</div>
</div>
<div class="col-xs-5 col-sm-4 hidden-print">
<div class="pull-right">
<script type="text/javascript"> 
										      (function(d, t) { 
										        var s = d.createElement(t), options = {'domain':'papyrus.bib.umontreal.ca','style': '16','container':'entrust-net-seal'}; 
										        s.src = 'https://seal.entrust.net/sealv2.js'; 
										        s.async = true; 
										        var scr = d.getElementsByTagName(t)[0], par = scr.parentNode; par.insertBefore(s, scr); 
										        s.onload = s.onreadystatechange = function() { 
										        var rs = this.readyState; if (rs) if (rs != 'complete') if (rs != 'loaded') return; 
										        try{goEntrust(options)} catch (e) {} }; 
										        })(document, 'script'); 
										</script>
<div id="entrust-net-seal">
<a href="https://www.entrust.com/ssl-certificates/">Certificat SSL / SSL Certificate</a>
</div>
</div>
</div>
</div>
<div class="row bib-footer hidden-print">
<div class="col-xs-12 col-sm-12 col-md-4">
<a class="footerEXLlink" href="http://www.bib.umontreal.ca"><img alt="les bibliothèques/UdeM" src="/xmlui/themes/Mirage2/images/propulse-par.png"/></a>
</div>
<div class="hidden-xs col-sm-12 col-md-8">
<nav>
<ul>
<li>
<a href="https://www.urgence.umontreal.ca/">Emergency</a>
</li>
<li>
<a href="http://www.carrieres.umontreal.ca/">Careers</a>
</li>
<li>
<a href="https://outlook.umontreal.ca/">My email</a>
</li>
<li>
<a href="https://studium.umontreal.ca/">StudiUM</a>
</li>
<li>
<a href="http://itunesu.umontreal.ca/">iTunes U</a>
</li>
<li>
<a href="http://www.bib.umontreal.ca/a-propos/nous-ecrire.htm">Contact us</a>
</li>
<li>
<a href="https://www.facebook.com/bibUdeM"><img alt="Facebook" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-Facebook.png"/></a>
</li>
<li>
<a href="https://www.youtube.com/user/BibliothequesUdeM"><img alt="YouTube" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-YouTube.png"/></a>
</li>
<li>
<a href="https://twitter.com/bibUdeM"><img alt="Twitter" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-Twitter.png"/></a>
</li>
<li>
<a href="https://www.nouvelles.umontreal.ca/frontpage/rss.html"><img alt="University RSS" src="/xmlui/themes/Mirage2/images/bib-umontreal/icone-syndication-14x14.png"/></a>
</li>
</ul>
</nav>
</div>
</div>
<a class="hidden" href="/xmlui/htmlmap"> </a>
<p> </p>
</footer>
</div>
</div>
</div>
</div>
<div class="hidden-xs hidden-sm">
<footer>
<div class="row">
<hr/>
<div class="col-xs-7 col-sm-8">
<div>
<a href="http://www.dspace.org/" target="_blank">DSpace software</a>
                        [version 5.8 XMLUI],
                        copyright © 2002-2015  <a href="http://www.duraspace.org/" target="_blank">DuraSpace</a>
</div>
<div class="hidden-print">
<a href="/xmlui/contact">Contact Us</a> | <a href="/xmlui/feedback">Send Feedback</a>
</div>
</div>
<div class="col-xs-5 col-sm-4 hidden-print">
<div class="pull-right">
<script type="text/javascript"> 
										      (function(d, t) { 
										        var s = d.createElement(t), options = {'domain':'papyrus.bib.umontreal.ca','style': '16','container':'entrust-net-seal'}; 
										        s.src = 'https://seal.entrust.net/sealv2.js'; 
										        s.async = true; 
										        var scr = d.getElementsByTagName(t)[0], par = scr.parentNode; par.insertBefore(s, scr); 
										        s.onload = s.onreadystatechange = function() { 
										        var rs = this.readyState; if (rs) if (rs != 'complete') if (rs != 'loaded') return; 
										        try{goEntrust(options)} catch (e) {} }; 
										        })(document, 'script'); 
										</script>
<div id="entrust-net-seal">
<a href="https://www.entrust.com/ssl-certificates/">Certificat SSL / SSL Certificate</a>
</div>
</div>
</div>
</div>
<div class="row bib-footer hidden-print">
<div class="col-xs-12 col-sm-12 col-md-4">
<a class="footerEXLlink" href="http://www.bib.umontreal.ca"><img alt="les bibliothèques/UdeM" src="/xmlui/themes/Mirage2/images/propulse-par.png"/></a>
</div>
<div class="hidden-xs col-sm-12 col-md-8">
<nav>
<ul>
<li>
<a href="https://www.urgence.umontreal.ca/">Emergency</a>
</li>
<li>
<a href="http://www.carrieres.umontreal.ca/">Careers</a>
</li>
<li>
<a href="https://outlook.umontreal.ca/">My email</a>
</li>
<li>
<a href="https://studium.umontreal.ca/">StudiUM</a>
</li>
<li>
<a href="http://itunesu.umontreal.ca/">iTunes U</a>
</li>
<li>
<a href="http://www.bib.umontreal.ca/a-propos/nous-ecrire.htm">Contact us</a>
</li>
<li>
<a href="https://www.facebook.com/bibUdeM"><img alt="Facebook" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-Facebook.png"/></a>
</li>
<li>
<a href="https://www.youtube.com/user/BibliothequesUdeM"><img alt="YouTube" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-YouTube.png"/></a>
</li>
<li>
<a href="https://twitter.com/bibUdeM"><img alt="Twitter" src="/xmlui/themes/Mirage2/images/bib-umontreal/logo-Twitter.png"/></a>
</li>
<li>
<a href="https://www.nouvelles.umontreal.ca/frontpage/rss.html"><img alt="University RSS" src="/xmlui/themes/Mirage2/images/bib-umontreal/icone-syndication-14x14.png"/></a>
</li>
</ul>
</nav>
</div>
</div>
<a class="hidden" href="/xmlui/htmlmap"> </a>
<p> </p>
</footer>
</div>
</div>
<script src="https://www.google.com/jsapi"> </script><script>if(!window.DSpace){window.DSpace={};}window.DSpace.context_path='/xmlui';window.DSpace.theme_path='/xmlui/themes/Mirage2/';</script><script src="/xmlui/themes/Mirage2/scripts/theme.js"> </script><script>
                  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
                  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
                  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
                  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

                  ga('create', 'UA-305727-1', 'papyrus.bib.umontreal.ca');
                  ga('send', 'pageview');
           </script><script>         
             var details_Papyrus =  $("#aspect_viewArtifacts_Navigation_list_account .details_Papyrus").text();
             $("#aspect_viewArtifacts_Navigation_list_account a[href='/xmlui/login']").attr("title",details_Papyrus);
        </script>
</body></html>
